Chris Ryan

Rusfertide improved responses vs placebo in phlebotomy-dependent polycythemia vera.

T-DXd improved overall survival in unresectable/metastatic HER2-positive gastric/GEJ adenocarcinoma after a trastuzumab-containing regimen.

The CHMP has recommend the approval of subcutaneous daratumumab plus VRd for newly diagnosed multiple myeloma.

The CHMP has recommended the European approval of pirtobrutinib for relapsed/refractory CLL previously treated with a covalent BTK inhibitor.

The CHMP has recommended the approval of trastuzumab deruxtecan for HER2-low or HER2-ultralow metastatic breast cancer.

Escalating doses of lymphodepleting chemotherapy with or without rituximab prior to CAR T-cell therapy was safe in relapsed/refractory DLBCL.

Isatuximab plus VRd has been approved in Japan for transplant-ineligible, newly diagnosed multiple myeloma.

Tambiciclib plus zanubrutinib generated responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

The FDA granted fast track designation to 67Cu-SAR-bisPSMA for PSMA-positive metastatic castration-resistant prostate cancer.

Petosemtamab/pembrolizumab received FDA breakthrough therapy designation for PD-L1–positive recurrent/metastatic head and neck squamous cell carcinoma.

Neoadjuvant nivolumab plus chemotherapy improved overall survival in resectable non–small cell lung cancer.

Detalimogene voraplasmid generated complete responses in BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ.

The FDA granted fast track designation to IBI363 for squamous non–small cell lung cancer.

The FDA and European Commission have approved 2 biosimilars referencing denosumab for cancer-related bone loss and other indications.

CD4-, FOXP3-, and Helios-positive conventional T cells were increased in patients receiving Orca-T vs peripheral blood stem cell grafts.

Zamto-cel produced responses and was associated with low rates of CD19 and/or CD20 antigen loss in relapsed/refractory diffuse large B-cell lymphoma.

A high-risk CAR-HEMATOTOX score was associated with worse outcomes with obe-cel in relapsed/refractory B-ALL.

The FDA approved brentuximab vedotin plus lenalidomide and rituximab for relapsed or refractory large B-cell lymphoma.

The FDA has approved mirdametinib for patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas.

Health Canada has approved perioperative pembrolizumab for resectable non–small cell lung cancer.

Zilovertamab vedotin generated responses and was safe in heavily pretreated relapsed/refractory mantle cell lymphoma.

The FDA has granted fast track designation to amezalpat for patients with hepatocellular carcinoma.

The combination of cabozantinib and nivolumab showed 16-week disease control in microsatellite stable colorectal cancer.

The FDA has granted breakthrough device designation to Serial CTRS for risk prognosis in non–small cell lung cancer.

The FDA has granted orphan drug designation to 225Ac-satoreotide for patients with small cell lung cancer.

THIO plus cemiplimab generated a potential survival benefit in pretreated advanced non–small cell lung cancer.

The FDA accepted a BLA seeking the approval of the pertuzumab biosimilar HLX11 for HER2-positive breast cancer.

The FDA has approved a companion diagnostic for trastuzumab deruxtecan in hormone receptor–positive, HER2-ultralow metastatic breast cancer.

Walter J. Curran, MD, discusses the evolving use of radiotherapy in small cell cancer and data supporting its optimal use.

Kathleen Moore, MD, MD, FASCO, discusses the development of antibody-drug conjugates in ovarian cancer and how they could shift the field.